Stratum Nutrition (St. Louis, MO) has announced that the company, in collaboration with its European partner KitoZyme (Herstal, Belgium), will soon begin a six-week human clinical study on Artinia, a chitin-glucan fiber marketed for heart health.
Stratum Nutrition (St. Louis, MO) has announced that the company, in collaboration with its European partner KitoZyme (Herstal, Belgium), will soon begin a six-week human clinical study on Artinia, a chitin-glucan fiber marketed for heart health.
Thus far, a 12-week animal and 30-day human pilot study have been performed on the ingredient. The upcoming study, which has received approval frmo an Institutional Review Board, will be randomized, double-blind, and placebo-controlled at three clinical sites. Biomarkers to be measured will include the oxidation of low-density lipoprotein (LDL or 'bad'ÃÂ cholesterol), lipids, insulin, and other markers related to inflammation and human safety.
The study is expected to be completed by the end of this year. For more information on the ingredient, visit Stratum Nutrition here.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.